GT Biopharma (GTBP) Corporate presentation summary

Proprietary platform and technology

• TriKE® platform uses tri-specific NK cell engagers with camelid nanobody technology to target cancer and autoimmune diseases.

• TriKE®s activate NK cells via CD16A and IL-15, targeting multiple tumor antigens including B7H3, HER2, CD33, and PDL1.

• Second-generation TriKE®s utilize nanobodies for improved potency, binding affinity, and manufacturing scalability.

• Platform enables modular targeting of both solid tumors and hematological malignancies.

• TriKE®s are designed to minimize toxicities such as cytokine release syndrome compared to T-cell therapies.

Clinical and pipeline progress

• GTB-3550 demonstrated proof of concept in Phase 1 for AML/MDS, showing NK cell activation and significant blast reduction in several patients.

• GTB-3650, a second-generation TriKE®, is in Phase 1 with first four cohorts enrolled as of June 2024.

• GTB-5550 targets B7H3 for solid tumors, with IND accepted in January 2026 and first patient dosed in May 2026.

• GTB-7550 is in development for lupus and other autoimmune disorders, targeting CD19 for B-cell depletion.

• Over six pipeline assets are in preclinical development, covering both oncology and autoimmune indications.

Financial position and leadership

• Approximately $5.1M in cash as of June 30, 2026, expected to fund operations through Q4 2026.

• Management team has deep expertise in oncology drug development and biotech financing.

• University of Minnesota holds a royalty interest in GTB-3650.